EUROB:ATHEXEUROBANK S.A. Analysis
Data as of 2026-05-27 - not real-time
€3.97
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Eurobank S.A. is trading at €3.97, comfortably above its 20‑day (€3.78), 50‑day (€3.69) and 200‑day (€3.56) simple moving averages, and the MACD histogram is positive with a bullish signal line, indicating momentum is still in the buyer’s camp. The RSI sits at 57.7, suggesting the stock is not overbought, while the 30‑day volatility of 46.5% and a decreasing volume trend temper the rally. With a current price near the midpoint of its support (€3.50) and resistance (€4.02) band, the model‑based upside of roughly 20% to a target of €4.76 appears achievable, though the high volatility and thinning volume warrant caution.
Fundamentally, Eurobank looks undervalued – its trailing P/E of 10.7 is well below the industry average of 16.7 and the price‑to‑book of 1.32 reflects a modest premium to book value. The bank posted a profit margin of 44.8% and a ROE of 13.7%, with revenue growing 8.5% YoY and Q1 FY2026 net profit of €351 million. A dividend yield of 3.02% paid at a 41% payout ratio, coupled with a strong cash buffer (€13.7 bn) against €11.9 bn debt, underpins the sustainability of shareholder returns. Analyst consensus is a “strong buy” with a median price target of €4.75, reinforcing the case for upside potential.
Fundamentally, Eurobank looks undervalued – its trailing P/E of 10.7 is well below the industry average of 16.7 and the price‑to‑book of 1.32 reflects a modest premium to book value. The bank posted a profit margin of 44.8% and a ROE of 13.7%, with revenue growing 8.5% YoY and Q1 FY2026 net profit of €351 million. A dividend yield of 3.02% paid at a 41% payout ratio, coupled with a strong cash buffer (€13.7 bn) against €11.9 bn debt, underpins the sustainability of shareholder returns. Analyst consensus is a “strong buy” with a median price target of €4.75, reinforcing the case for upside potential.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above all key SMAs
- Attractive upside to target price with support intact
- Moderate volatility but low beta reduces market risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued valuation metrics relative to peers
- Solid dividend yield and sustainable payout
- Strong earnings growth and improving profitability
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Low beta and stable cash generation support long‑term stability
- Consistent dividend policy provides income stream
- Strategic regional presence and expanding asset base
Key Metrics & Analysis
Financial Health
Revenue Growth8.50%
Profit Margin44.79%
P/E Ratio10.7
ROE13.68%
ROA1.31%
P/B Ratio1.3
Op. Cash Flow€-1895000064
Industry P/E16.7
Technical Analysis
TrendBullish
RSI57.7
Support€3.50
Resistance€4.02
MA 20€3.78
MA 50€3.69
MA 200€3.56
MACDBullish
VolumeDecreasing
Fear & Greed Index91.13
Valuation
Target Price€4.76
Upside/Downside19.80%
GradeUndervalued
TypeBlend
Dividend Yield3.02%
Risk Assessment
Beta0.49
Volatility46.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.